Coronary Artery DiseasePhase 4NCT00977938
The Dual Antiplatelet Therapy Study (DAPT Study)
A Phase 4 study testing Clopidogrel & Aspirin, Prasugrel & Aspirin in people with Coronary Artery Disease, run by Baim Institute for Clinical Research at 256 sites in 10 countries.
Trial summary
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 25,682 participants
- Where
- 256 sitesin 10 countries
- Study dates
- Oct 2009to Jun 2014
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject is > 18 years of age.
- Subjects undergoing percutaneous intervention with stent deployment (or has w/in 24 hours).
- Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation.
- The subject has consented to participate and has authorized the collection and release of his medical information by signing the "Patient Informed Consent Form". The informed consent will be valid for the duration of the trial or until the subject withdraws.
- 1. Subject, at 12 months, is free from death, MI, stroke, repeat coronary revascularization, major bleeding, and stent thrombosis and has been compliant with dual antiplatelet therapy following stent implantation.
Who cannot join
- Index procedure stent placement with stent diameter <2.25 mm or >4.0 mm.
- Pregnant women.
- Planned surgery necessitating discontinuation of antiplatelet therapy within the 30 months following enrollment.
- Current medical condition with a life expectancy of less than 3 years.
- Concurrent enrollment in another device or drug study whose protocol specifically excludes concurrent enrollment or that involves blinded placement of a DES or BMS other than those included as DAPT Study devices. The subject may only be enrolled in the DAPT Study once.
- Subjects on warfarin or similar anticoagulant therapy.
Show all 15Show fewer
- Subjects with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use for the device implanted.
- Subjects unable to give informed consent.
- Subject treated with both DES and BMS during the index procedure.
- Pregnant women.
- Subject switched thienopyridine type or dose within 6 months prior to randomization.
- Percutaneous coronary intervention or cardiac surgery between 6 weeks post index procedure and randomization.
- Planned surgery necessitating discontinuation of antiplatelet therapy within the 21 months following randomization.
- Current medical condition with a life expectancy of less than 3 years.
- Subjects on warfarin or similar anticoagulant therapy.
Trial locations and contacts
256 sites in 10 countries.
256 sites in 10 countries
United States178 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Presbyterian Heart Group
Albuquerque, New Mexico, 87106
McFarland Clinic PC
Ames, Iowa, 50010
AnMed Health
Anderson, South Carolina, 29621
Asheville Cardiology Associates
Asheville, North Carolina, 28802
Kings Daughters Medical Center
Ashland, Kentucky, 41101
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Piedmont Hospital Research Institute
Atlanta, Georgia, 30309
Emory University Hospital
Atlanta, Georgia, 30322
Palm Beach Heart Research Institute
Atlantis, Florida, 33462
Medical Center of Aurora
Aurora, Colorado, 80012
Austin Heart
Austin, Texas, 78705
Capital Cardiovascular Research Institute
Austin, Texas, 78745
Texas Cardiovascular
Austin, Texas, 78758
Sinai Hospital at Baltimore
Baltimore, Maryland, 21215
Union Memorial Hospital
Baltimore, Maryland, 21218
Northeast Cardiology Associates
Bangor, Maine, 04401
Advocate Good Shephard Hospital
Barrington, Illinois, 60010
Bay Regional Medical Center
Bay City, Michigan, 48708
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Boston Medical Center
Boston, Massachusetts, 02118
Brigham and Women's Hospital
Boston, Massachusetts, 02120
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Bay Area Cardiology Associates/ Brandon Regional Hospital
Brandon, Florida, 33511
Connecticut Clinical Research, LLC
Bridgeport, Connecticut, 06606
Bridgeport Hospital
Bridgeport, Connecticut, 06610
Lahey Clinic Medical Center
Burlington, Massachusetts, 01805
Cooper University Hospital
Camden, New Jersey, 08103
St. Luke's Hospital - Cedar Rapids
Cedar Rapids, Iowa, 52403
Chambersburg Hospital
Chambersburg, Pennsylvania, 17201
Carolinas Medical Center
Charlotte, North Carolina, 28203
University of Virginia
Charlottesville, Virginia, 22908
Chattanooga Heart - East Third Street
Chattanooga, Tennessee, 37404
Chattanooga Heart Institute
Chattanooga, Tennessee, 37404
Jesse Brown VA Medical Center
Chicago, Illinois, 60612
Rush University Medical Center
Chicago, Illinois, 60612
University of Illinois at Chicago
Chicago, Illinois, 60612
The Lindner Clinical Trial Center
Cincinnati, Ohio, 45219
Good Samaritan Hospital
Cincinnati, Ohio, 45220
University of Cincinnati Medical Center
Cincinnati, Ohio, 45267-0542
Riverside Methodist
Columbus, Ohio, 43214
Veteran's Affairs Medical Center- Dallas
Dallas, Texas, 75216
CRSTI Research
Dallas, Texas, 75230
UT Southwestern Medical Center
Dallas, Texas, 75390
Geisinger Clinic
Danville, Pennsylvania, 17822
Harper University Hospital
Detroit, Michigan, 48201-2018
Henry Ford Hospital Heart & Vascular Institute
Detroit, Michigan, 48202
Good Samaritan Hospital- IL
Downers Grove, Illinois, 60515
Doylestown Hospital
Doylestown, Pennsylvania, 18901
Midwest Cardiovascular Research and Education Foundation
Elkhart, Indiana, 46541
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Elyria Memorial Hospital
Elyria, Ohio, 44035
Thomas Hospital
Fairhope, Alabama, 36532
MeritCare Medical Center
Fargo, North Dakota, 58122
California Cardiovascular Consultants/ Washington Hospital
Fremont, California, 94538
Carolina Heart Specialists
Gastonia, North Carolina, 28054
Mercy Gilbert Medical Center
Gilbert, Arizona, 85297
Altru Health System
Grand Forks, North Dakota, 58206
Cardiovascular Associates of the Delaware Valley, PA
Haddon Heights, New Jersey, 08035
Hamilton Cardiology Associates
Hamilton, New Jersey, 08690
Pinnacle Health Hospital
Harrisburg, Pennsylvania, 17110
Rockingham Memorial Hospital
Harrisonburg, Virginia, 22801
Hattiesburg Clinic
Hattiesburg, Mississippi, 39401
Valley Hospital
Hawthorne, New Jersey, 07506
Carolina Cardiology Associates
High Point, North Carolina, 27262
Methodist DeBakey Heart & Vascular Center
Houston, Texas, 77030
Cape Cod Hospital
Hyannis, Massachusetts, 02601
St. Vincent Heart Center of Indiana, LLC
Indianapolis, Indiana, 46290
Jacksonville Heart Center
Jacksonville, Florida, 32207
Conemaugh Memorial Medical Center
Johnstown, Pennsylvania, 15905
Heartland Education and Research Foundation
Joliet, Illinois, 60435
NEA Baptist Clinic
Jonesboro, Arkansas, 72401
Borgess Medical Center
Kalamazoo, Michigan, 49048
St. Luke's Hospital Mid America Heart Institute
Kansas City, Missouri, 64111
Kansas City Heart Foundation
Kansas City, Missouri, 64114
The Foundation for Cardiovascular Medicine
La Jolla, California, 92037
Watson Clinic Center for Research
Lakeland, Florida, 33805
Diagnostic Cardiology Associates
Lauderdale Lakes, Florida, 33313
Nebraska Heart Institute
Lincoln, Nebraska, 68526
University of Arkansas (Central VA) for Medical Science
Little Rock, Arkansas, 72205
Arkansas Heart Hospital
Little Rock, Arkansas, 72211
SJH Cardiology Associates
Liverpool, New York, 13088
Lynchburg General Hospital
Lynchburg, Virginia, 24501
Medical Center Central Georgia
Macon, Georgia, 31201
Catholic Medical Center
Manchester, New Hampshire, 03102
Frederick C Smith Clinic dba Smith Clinic
Marion, Ohio, 43302
Loyola University Medical Center
Maywood, Illinois, 60153
North Dallas Research Associates
McKinney, Texas, 75069
North Dallas Research Associate
McKinney, Texas, 75069
Melbourne Internal Medicine Assoc
Melbourne, Florida, 32901
Baptist Hospital of Miami
Miami, Florida, 33176
Midwest Regional Medical Center
Midwest City, Oklahoma, 73110
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Winthrop University Hospital
Mineola, New York, 11501
Heart Care Research Foundation
Mokena, Illinois, 60448
Intermountain Medical Center
Murray, Utah, 84157-7000
Edward Heart Hospital
Naperville, Illinois, 60540
Centennial Heart Medical Center
Nashville, Tennessee, 37203
UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
Tulane University Medical School
New Orleans, Louisiana, 70112
St. Michaels Hospital
Newark, New Jersey, 07102
Sentara, Norfolk General Hospital
Norfolk, Virginia, 23507
North Kansas City Hospital
North Kansas City, Missouri, 64116
Munroe Regional Medical Center
Ocala, Florida, 34471
Ocala Regional Medical Center
Ocala, Florida, 34480
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Oklahoma Foundation for CV Research
Oklahoma City, Oklahoma, 73120
Providence St. Peter Hospital
Olympia, Washington, 98506
Alegent Health / Bergan Mercy Hospital
Omaha, Nebraska, 68124
Creighton University
Omaha, Nebraska, 68131
Florida Hospital
Orlando, Florida, 32803
Baptist Hospital
Pensacola, Florida, 32501
Sacred Heart Hospital
Pensacola, Florida, 32504
Heart & Vascular Center of Arizona
Phoenix, Arizona, 85006
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, 15213
The Heart Hospital / Baylor Plano
Plano, Texas, 75093
St. Joseph Mercy-PTCMI
Pontiac, Michigan, 48341
Maine Medical Center
Portland, Maine, 04102
St. Vincent Hospital/ Providence Heart Hospital
Portland, Oregon, 97225
Oregon Health & Sciences University Hospital
Portland, Oregon, 97239-3098
Hudson Valley Heart Center
Poughkeepsie, New York, 12601
Shah Associates, LLC
Prince Frederick, Maryland, 20678
Rhode Island Hospital
Providence, Rhode Island, 02903
Miriam Hospital
Providence, Rhode Island, 02904
Wake Heart Association
Raleigh, North Carolina, 27610
Black Hills Research- Rapid City Regional
Rapid City, South Dakota, 57701
Carilion Clinic
Roanoke, Virginia, 24014
Mayo Clinic - Saint Marys Hospital
Rochester, Minnesota, 55905
Redmond Regional Hospital
Rome, Georgia, 30165
Scott and White Healthcare - Round Rock
Round Rock, Texas, 78665
William Beaumont Hospital
Royal Oak, Michigan, 48073-6769
Mercy General Hospital
Sacramento, California, 95819
Covenant Medical Center
Saginaw, Michigan, 48602
Central Minnesota Heart Center at St. Cloud Hospital
Saint Cloud, Minnesota, 56303
Great Lakes Heart & Vascular Institute, PC
Saint Joseph, Michigan, 49085
Peninsula Regional Medical Center
Salisbury, Maryland, 21804
TexSan Heart Hospital
San Antonio, Texas, 78229
UC San Diego Medical Center
San Diego, California, 92103-8784
California Pacific Medical Center
San Francisco, California, 94115
Donald Guthrie Foundation for Education and Research
Sayre, Pennsylvania, 18840
Scottsdale Health Care
Scottsdale, Arizona, 85258
University of Washington
Seattle, Washington, 98195-8422
North Central Heart Institute
Sioux Falls, South Dakota, 57105
Sanford USD Medical Center
Sioux Falls, South Dakota, 57117
Inland Cardiology Associates
Spokane, Washington, 99204
Sacred Heart Medical Center
Spokane, Washington, 99204
St. John's Medical Institute
Springfield, Missouri, 65807
Washington University Hospital
St Louis, Missouri, 63110-1093
St. Louis University Hospital
St Louis, Missouri, 63110
St. John's Mercy Medical Center
St Louis, Missouri, 63141
St. Vincent's Medical Center
Stamford, Connecticut, 06905
St. Joseph's Medical Center- CA
Stockton, California, 95204-6088
Stony Brook University Medical Center
Stony Brook, New York, 11794-8167
Washington Adventist Hospital
Takoma Park, Maryland, 20912
Tallahassee Memorial Hospital
Tallahassee, Florida, 32308
Pepin Heart Hospital
Tampa, Florida, 33613
Northwest Ohio Cardiology
Toledo, Ohio, 43615
Torrance Memorial Medical Center / Vasek Polak Research Program
Torrance, California, 90505
Harbor - UCLA Medical Center
Torrance, California, 90509
Munson Medical Center
Traverse City, Michigan, 49684
Beaumont Hospital Troy
Troy, Michigan, 48085
Cardiology Associates Research LLC
Tupelo, Mississippi, 38801
Mother Frances Hospital
Tyler, Texas, 75701
St. Elizabeth's Medical Center- NY
Utica, New York, 13501
Westchester Medical Center
Valhalla, New York, 10595
Northwest Indiana Cardiovascular Physicians, P.C.
Valparaiso, Indiana, 46383
Cardiovascular Associates, Ltd.
Virginia Beach, Virginia, 23454
Providence Healthcare Network
Waco, Texas, 76712
Washington Hospital Center
Washington D.C., District of Columbia, 20010
CaRE Foundation, Inc.
Wausau, Wisconsin, 54401
Iowa Heart Center
West Des Moines, Iowa, 50266
Winchester Medical Center
Winchester, Virginia, 22601
Forsyth Medical Center
Winston-Salem, North Carolina, 27103
Wake Forest Health Sciences
Winston-Salem, North Carolina, 27157-1045
Winter Haven Hospital
Winter Haven, Florida, 33881
UMass Memorial Medical Center
Worcester, Massachusetts, 01655
Berks Cardiologists
Wyomissing, Pennsylvania, 19610
York Hospital (PA)
York, Pennsylvania, 17403
United Kingdom18 sites
Barnet Hospital
Barnet, Herts, EN5 3DJ
Basildon University Hospital
Basildon, Essex, SS16 5NL
Royal Bournemouth General Hospital
Bournemouth, Dorset, BH7 7DW
Papworth Hospital
Cambridge, Cambs, CB3 8RE
St Peter's Hospital
Chertsey, KT16 OPZ
University Hospital of Coventry and Warwickshire
Coventry, CV2 2DX
Ninewells Hospital
Dundee, Scotland, DD1 9SY
Ninewells Hospital
Dundee, DD1 9SY
Royal Infirmary of Edinburgh
Edinburgh, EH16 4SA
Golden Jubilee National Hospital
Glasgow, Strath, F81 4HX
Wycombe General Hospital
High Wycombe, Bucks, HP11 2TT
University Hospital of Leicester Glenfield Hospital
Leicester, LE3 9QP
The London Chest Hospital
London, E2 9JX
James Cook Hospital
Middlesbrough, N York, TS4 3BW
Freeman Hospital
Newcastle, NE7 7AW
Derriford Hospital
Plymouth, PL6 8DH
Torbay hospital
Torquay, Devon, TQ2 7AA
Weston General Hospital
Weston-super-Mare, Somerset, BS23 4TQ
Germany11 sites
Helios Klinikum Emil von Behring
Berlin, State of Berlin, 1
Vivantes Klinikum im Friedrichshain
Berlin, 10249
Vivantes-Klinikum Neukoelin
Berlin, 12351
Vivantes-Klinikum Neukoelln
Berlin, 13437
Vivantes-Humboldt Klinikum
Berlin, 13509
Elbe-Kliniken Stade-Buxtehude GmbH
Buxtehude, 21614
Universitaetsklinikum Dresden
Dresden, 01307
Asklepios Klinik St. Georg
Hamburg, 20099
Herzzentrum Leipzig GmbH
Leipzig, 4289
Universitaetsklinikum Schleswig-Holstein - PS
Lübeck, Schleswig-Holstein, 23538
Elbe-Kliniken Stade-Buxtehude GmbH
Stade, 21682
Australia9 sites
Royal Adelaide Hospital
Adelaide, South Australia, 5000
Monash Heart
Clayton, 3168
St. Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010
St Vincents Hospital Melbourne
Fitzroy, 3065
Fremantle Hospital
Fremantle, Western Australia, 6160
The Mount Hospital
Nedlands, Western Australia, 6009
Royal Perth Hospital
Perth, Western Australia, 6000
The Alfred Hospital
Prahran, Victoria, 3004
Prince of Wales Eastern Heart
Randwick, New South Wales, 2031
New Zealand9 sites
North Shore Hospital
Auckland, 0622
Ascot Hospital
Auckland
Middlemore Hospital
Auckland
Christchurch Hospital
Christchurch, 8001
Mercy Angiography
Epsom, Auckland, 00000
Waikato Hospital
Hamilton, 3240
Nelson Hospital
Nelson
Wellington Hospital
Wellington, 6021
Wakefield Hospital
Wellington, 6039
France7 sites
Centre Hospitalier Saint Louis
La Rochelle, 17000
Hospital Saint Philibert
Lomme, 59462
Nouvelles Cliniques Nantaises
Nantes, 44277
Clinique les Franciscaines
Nîmes, 30000
Hopital Bichat
Paris, 75018
Groupe Hospitalier Sud
Pessac, 33604
CH Chatiliez Tourcoing
Tourcoing, 59208
Poland7 sites
Uniwersyteck Szpital Klin. w Bialymstoku
Bialystok, 15-276
Wielospecj. Szpital Miejski im.dr.E.Warminskiego-SPZOZ
Bydgoszcz, 85-826
NZOZ Centrum Medyczne Beluga-Med
Krakow, 30-069
Szpital Uniwersytecki w Krakowie
Krakow, 31-501
SPSK nr 2 Pomorskiej Akademii Medycznej w Szczecinie
Szczecin, 70-111
Polsko-Amerykanskie Kliniki Serca.American Heart of Poland S
Ustroń, 43-450
Instytut Kardiologii im. Kardynala St. Wyszynskiego
Warsaw, 04-637
Romania7 sites
Centrul Clinic de Urgenta de Boli Cardiovasculare al Armatei
Bucharest, 10242
Spitalul Clinic de Urgenta Bucuresti
Bucharest, 14461
Inst. Urgenta Boli Cardiovasculare Prof. Dr. C.C. Iliescu
Bucharest, 22328
Institutul de Urgenta pentru Boli Cardiovasculare Prof. Dr.
Bucharest, 22328
Spitalul Clinic Universitar de Urgenta Bucuresti
Bucharest, 50098
Institutul Inimii Niculae Stancioiu Cluj-Napoca
Cluj-Napoca, 400001
Institutul de Boli Cardiovasculare si Transplant Targu Mures
Târgu Mureş, 540136
Czechia5 sites
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05
Krajska karlovarska nemocnice a.s.
Karlovy Vary, 360 66
Centrum pro choroby srdce a cev
Kroměříž, 767 01
Mestska nemocnice Ostrava
Ostrava, 701 00
Krajska nemocnice T. Bati a.s.
Zlín, 76275
Hungary5 sites
Gottsegen Gyorgy Orszagos Kardiologiai Intezet
Budapest, 1096
Josa Andras Oktato Korhaz Nonprofit Kft
Nyíregyháza, 4400
Pecsi Tudomanyegyetem Klinikai Kozpont
Pécs
Szegedi Tudomanyegyetem Szent-Gyorgyi Klinikai Kozpont
Szeged, 6720
Zala Megyei Korhaz
Zalaegerszeg, 8900
About this study
Official title: A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.
Read the detailed description
Subjects with ischemic heart disease due to stenotic lesions in either native coronary arteries or coronary artery bypass grafts undergoing percutaneous coronary intervention (PCI) with stent placement and no contraindications to prolonged dual antiplatelet therapy are eligible to be enrolled in the study.
All enrolled subjects will undergo PCI with stent placement. All enrolled subjects will be treated with either an FDA-approved drug eluting stent(s) (DES) or an FDA-approved bare metal stent(s) (BMS) (per their respective Instructions for Use) and assigned to 12 months of open label FDA-approved thienopyridine treatment in addition to aspirin. Operators will select the thienopyridine according to the package insert. Thienopyridine treatment dose will be according to the standard of practice and prescribing information for the selected medication. Aspirin treatment will be 75-325 mg for the first 6 months after the procedure and 75-162 mg subsequently, to be continued indefinitely. All DES or BMS subjects who are treated with 12 months of dual antiplatelet therapy post index procedure and who are event free per protocol will be eligible for randomization to either placebo (12 m DAPT Study arm) or an additional 18 months of thienopyridine treatment (30 m DAPT Study arm). Both arms will continue aspirin therapy.
Up to four (4) separate post-market approval studies will be allowed to incorporate the randomized design of the DAPT Study for a subset of subjects who may then be contributed for the DAPT Study analyses.
- Conditions
- Coronary Artery Disease
- Being tested
- Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
- Keywords
- Acute Coronary Syndrome, Adverse event, Antiplatelet therapy, Sirolimus, Everolimus, Paclitaxel, Zotarolimus, Bare Metal Stent, Drug Eluting Stent, Clinical Events Committee, Dual antiplatelet therapy, Harvard Clinical Research Institute, Major Adverse Cardiac and Cerebral Event, Major Bleeding, Myocardial infarction, Myocardial ischemia, Percutaneous coronary intervention, Stent placement, Stent Thrombosis, Thienopyridine
- Medical subject headings
- Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo & AspirinDrug
Clopidogrel & Aspirin, Prasugrel & AspirinDrug
| Study group | Role | What they receive |
|---|---|---|
| 12m DAPT Study Arm | Placebo comparator | This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin. Receives: Drug: Placebo & Aspirin |
| 30m DAPT Study Arm | Active comparator | This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin. Receives: Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.
Measured: 18 months (12-30 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.
Measured: 18 months (12-30 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Measured: 18 months (12-30 months post-index procedure)
Secondary outcomes (11)
MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS
Secondary powered endpoint
Measured: 33 months (0-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS
Secondary powered endpoint
Measured: 33 months (0-33 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
Measured: 21 months (12-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Measured: 21 months (12-33 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Measured: 21 months (12-33 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Measured: 18 months (12-30 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Measured: 18 months (12-30 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Measured: 18 months (12-30 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Measured: 21 months (12-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
ST was assessed according to the Academic Research Consortium (ARC) definitions.
Measured: 21 months (12-33 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
Measured: 21 months (12-33 months post-index procedure)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2009 (estimated)
- Study startOct 2009
- Primary completionJun 2014
- Study completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (20)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 25,682 participants (actual)
Sponsor and investigators
- Lead sponsor
- Baim Institute for Clinical Research
- Sponsor type
- University, hospital or other
- Collaborators
- Abbott, Boston Scientific Corporation, Bristol-Myers Squibb, Sanofi-Synthelabo, Cordis US Corp., Eli Lilly and Company, Daiichi Sankyo, Medtronic
- Responsible party
- Sponsor
- Investigators
- Laura Mauri, MD, MSc, Principal investigator, Brigham and Women's HospitalDean Kereiakes, MD, FACC, Principal investigator, Christ Hospital Heart and Vascular Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00977938
- Sponsor's protocol ID
- HCRIG080186
- Status last verified
- May 2017
- First submitted
- 14 Sep 2009
- Last updated
- 9 Jun 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky EA, Yeh RW. Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. J Am Heart Assoc. 2023 Jul 18;12(14):e029588. doi: 10.1161/JAHA.123.029588. Epub 2023 Jul 14.
PubMed 37449567Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr;51(3):675-681. doi: 10.1007/s11239-020-02221-5.
PubMed 32683645Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE; DAPT Investigators. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 Dec 15;124(12):1813-1820. doi: 10.1016/j.amjcard.2019.09.006. Epub 2019 Sep 26.
PubMed 31653353Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L; DAPT Study Investigators. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 Aug;11(8):e005308. doi: 10.1161/CIRCINTERVENTIONS.117.005308.
PubMed 30354781Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L; DAPT Study Investigators. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31;70(18):2213-2223. doi: 10.1016/j.jacc.2017.09.011.
PubMed 29073947Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 May 1;2(5):478-487. doi: 10.1001/jamacardio.2017.0063.
PubMed 28297015Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 2;135(18):1720-1732. doi: 10.1161/CIRCULATIONAHA.116.024835. Epub 2017 Feb 22.
PubMed 28228427Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 4;134(14):989-998. doi: 10.1161/CIRCULATIONAHA.116.024531. Epub 2016 Aug 30.
PubMed 27576774Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L; DAPT Study Investigators. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31;67(21):2492-502. doi: 10.1016/j.jacc.2016.03.485. Epub 2016 Apr 1.
PubMed 27046159Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.
PubMed 27022822Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR Jr, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 3;133(18):1772-82. doi: 10.1161/CIRCULATIONAHA.115.016783. Epub 2016 Mar 18.
PubMed 26994121Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001.
PubMed 26793956Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21;37(4):378-85. doi: 10.1093/eurheartj/ehv614. Epub 2015 Nov 18.
PubMed 26586780Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct;8(12):1552-62. doi: 10.1016/j.jcin.2015.05.026.
PubMed 26493248Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26;65(20):2211-21. doi: 10.1016/j.jacc.2015.03.003. Epub 2015 Mar 15.
PubMed 25787199
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions
- ClinicalTrials.gov ID
- NCT00977938
- Acronym / sponsor ID
- HCRIG080186
- Conditions
- Coronary Artery Disease
- Keywords
- Acute Coronary Syndrome, Adverse event, Antiplatelet therapy, Sirolimus, Everolimus, Paclitaxel, Zotarolimus, Bare Metal Stent
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25,682 participants (actual)
- Lead sponsor
- Baim Institute for Clinical ResearchUniversity, hospital or other
- Collaborators
- Abbott, Boston Scientific Corporation, Bristol-Myers Squibb, Sanofi-Synthelabo, Cordis US Corp., Eli Lilly and Company, Daiichi Sankyo, Medtronic
- Study start
- Oct 2009
- Primary completion
- Jun 2014 (actual)
- Study completion
- Jun 2014 (actual)
- First posted
- 16 Sep 2009 (estimated)
- Results
- Posted 22 Oct 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.
Detailed description
Subjects with ischemic heart disease due to stenotic lesions in either native coronary arteries or coronary artery bypass grafts undergoing percutaneous coronary intervention (PCI) with stent placement and no contraindications to prolonged dual antiplatelet therapy are eligible to be enrolled in the study.
All enrolled subjects will undergo PCI with stent placement. All enrolled subjects will be treated with either an FDA-approved drug eluting stent(s) (DES) or an FDA-approved bare metal stent(s) (BMS) (per their respective Instructions for Use) and assigned to 12 months of open label FDA-approved thienopyridine treatment in addition to aspirin. Operators will select the thienopyridine according to the package insert. Thienopyridine treatment dose will be according to the standard of practice and prescribing information for the selected medication. Aspirin treatment will be 75-325 mg for the first 6 months after the procedure and 75-162 mg subsequently, to be continued indefinitely. All DES or BMS subjects who are treated with 12 months of dual antiplatelet therapy post index procedure and who are event free per protocol will be eligible for randomization to either placebo (12 m DAPT Study arm) or an additional 18 months of thienopyridine treatment (30 m DAPT Study arm). Both arms will continue aspirin therapy.
Up to four (4) separate post-market approval studies will be allowed to incorporate the randomized design of the DAPT Study for a subset of subjects who may then be contributed for the DAPT Study analyses.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 12m DAPT Study Arm | Placebo comparator | Drug: Placebo & AspirinThis population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin. |
| 30m DAPT Study Arm | Active comparator | Drug: Clopidogrel & Aspirin, Prasugrel & AspirinThis population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subject is > 18 years of age.
- Subjects undergoing percutaneous intervention with stent deployment (or has w/in 24 hours).
- Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation.
- The subject has consented to participate and has authorized the collection and release of his medical information by signing the "Patient Informed Consent Form". The informed consent will be valid for the duration of the trial or until the subject withdraws.
- 1. Subject, at 12 months, is free from death, MI, stroke, repeat coronary revascularization, major bleeding, and stent thrombosis and has been compliant with dual antiplatelet therapy following stent implantation.
Key exclusion criteria (15 listed)
- Index procedure stent placement with stent diameter <2.25 mm or >4.0 mm.
- Pregnant women.
- Planned surgery necessitating discontinuation of antiplatelet therapy within the 30 months following enrollment.
- Current medical condition with a life expectancy of less than 3 years.
- Concurrent enrollment in another device or drug study whose protocol specifically excludes concurrent enrollment or that involves blinded placement of a DES or BMS other than those included as DAPT Study devices. The subject may only be enrolled in the DAPT Study once.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo & Aspirin | Drug | 12m DAPT Study Arm |
| Clopidogrel & Aspirin, Prasugrel & Aspirin | Drug | 30m DAPT Study Arm |
Primary outcome
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
Time frame: 18 months (12-30 months post-index procedure)
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure.
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
Time frame: 18 months (12-30 months post-index procedure)
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions.
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
Time frame: 18 months (12-30 months post-index procedure)
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.
11 secondary outcomes
MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS
Time frame: 33 months (0-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS
Time frame: 33 months (0-33 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
Time frame: 21 months (12-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
Time frame: 21 months (12-33 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized DES ITT
Time frame: 21 months (12-33 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Time frame: 18 months (12-30 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
Time frame: 18 months (12-30 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Time frame: 18 months (12-30 months post-index procedure)
MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
Time frame: 21 months (12-33 months post-index procedure)
Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
Time frame: 21 months (12-33 months post-index procedure)
GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
Time frame: 21 months (12-33 months post-index procedure)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37449567Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky EA, Yeh RW. Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. J Am Heart Assoc. 2023 Jul 18;12(14):e029588. doi: 10.1161/JAHA.123.029588. Epub 2023 Jul 14.
- Derived from this study: PubMed 32683645Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr;51(3):675-681. doi: 10.1007/s11239-020-02221-5.
- Derived from this study: PubMed 31653353Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE; DAPT Investigators. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 Dec 15;124(12):1813-1820. doi: 10.1016/j.amjcard.2019.09.006. Epub 2019 Sep 26.
- Derived from this study: PubMed 30354781Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L; DAPT Study Investigators. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 Aug;11(8):e005308. doi: 10.1161/CIRCINTERVENTIONS.117.005308.
- Derived from this study: PubMed 29073947Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L; DAPT Study Investigators. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31;70(18):2213-2223. doi: 10.1016/j.jacc.2017.09.011.
- Derived from this study: PubMed 28297015Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 May 1;2(5):478-487. doi: 10.1001/jamacardio.2017.0063.
- Derived from this study: PubMed 28228427Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 2;135(18):1720-1732. doi: 10.1161/CIRCULATIONAHA.116.024835. Epub 2017 Feb 22.
- Derived from this study: PubMed 27576774Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 4;134(14):989-998. doi: 10.1161/CIRCULATIONAHA.116.024531. Epub 2016 Aug 30.
- Derived from this study: PubMed 27046159Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L; DAPT Study Investigators. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31;67(21):2492-502. doi: 10.1016/j.jacc.2016.03.485. Epub 2016 Apr 1.
- Derived from this study: PubMed 27022822Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.
- Derived from this study: PubMed 26994121Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR Jr, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 3;133(18):1772-82. doi: 10.1161/CIRCULATIONAHA.115.016783. Epub 2016 Mar 18.
- Derived from this study: PubMed 26793956Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001.
Related trials for Coronary Artery Disease
Recruiting
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
ST-Elevation Myocardial Infarction (STEMI)
Active, not recruiting
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Not yet recruiting
TRADENT Scoring Balloon Versus Non-scoring Balloon for Lesion Preparation in DCB-Based Coronary Intervention
Coronary Artery Disease (CAD)
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
RecruitingPhase 4
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laura Mauri, MD, MSc principal investigator
Brigham and Women's Hospital
Dean Kereiakes, MD, FACC principal investigator
Christ Hospital Heart and Vascular Center
256 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Clopidogrel & Aspirin, Prasugrel & Aspirin in people with Coronary Artery Disease, run by Baim Institute for Clinical Research at 256 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 256 sites in United States, United Kingdom, Germany, Australia, New Zealand and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Oct 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT (time frame: 18 months (12-30 months post-index procedure)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00977938, which also lists 20 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2017.